American International Group, Inc. Amylyx Pharmaceuticals, Inc. Transaction History

American International Group, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$2.71 - $19.57 $582 - $4,207	-215 Reduced 0.85%	25,031 $71,000
Q4 2023 Feb 13, 2024	SELL	$12.07 - $18.46 $1,231 - $1,882	-102 Reduced 0.4%	25,246 $371,000
Q3 2023 Nov 13, 2023	BUY	$18.08 - $23.45 $16,290 - $21,128	901 Added 3.69%	25,348 $464,000
Q2 2023 Aug 04, 2023	BUY	$20.98 - $31.42 $2,286 - $3,424	109 Added 0.45%	24,447 $527,000
Q1 2023 May 12, 2023	BUY	$27.71 - $40.93 $13,439 - $19,851	485 Added 2.03%	24,338 $714,000
Q4 2022 Feb 10, 2023	BUY	$29.75 - $39.26 $211,730 - $279,413	7,117 Added 42.53%	23,853 $881,000
Q3 2022 Nov 14, 2022	BUY	$17.15 - $30.92 $194,961 - $351,498	11,368 Added 211.77%	16,736 $471,000
Q2 2022 Aug 12, 2022	BUY	$6.85 - $19.93 $4,164 - $12,117	608 Added 12.77%	5,368 $103,000
Q1 2022 May 13, 2022	BUY	$12.85 - $32.9 $61,166 - $156,604	4,760 New	4,760 $61,000

140

44.6M

226K

909K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $180M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.